Healx Logo


We collaborate with academic, patient and industry groups to quickly progress new rare disease treatments through the clinic and towards patients

Healx Pipeline
In silico discovery
Preclinical validation
Clinical planning
Phase 1/2a
Fragile X syndrome
Pitt Hopkins syndrome
Autosomal dominant polycystic kidney disease (ADPKD)
Neurofibromatosis type 1 - cutaneous neurofibroma (cNF)
Neurofibromatosis type 1 - plexiform neurofibroma (pNF)
Chronic pancreatitis
Facioscapulohumeral muscular dystrophy (FSHD)
Friedreich's ataxia
Undisclosed disease
Undisclosed disease
Angelman syndrome
Undisclosed disease
Autosomal recessive polycystic kidney disease (ARPKD)
Undisclosed disease
Undisclosed disease
Undisclosed disease
Undisclosed disease
Rare neurodevelopmental
Rare renal
Rare oncology
Rare inflamatory
Rare neuromuscular
Rare respiratory
Rare bone
Rare eye

Ways of working together



True medical breakthroughs happen when industry, patient groups and academic institutions work together. And whilst cutting-edge AI technology is integral to our work, we recognise that without the involvement of our partners we couldn’t have achieved as much as we have done to date. 

We welcome enquiries from groups working on rare conditions where relevant assets, resources and data are available. If you are interested in partnering with us to progress treatments for your disease of interest please get in touch.

Contact us


Rare Treatment Accelerator

Our Rare Treatment Accelerator (RTA) helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to patients faster.

For all other questions, please email our team at accelerate@healx.io

Learn more